United States: At Long Last, CMS Issues Final Rule For Lab Fee Schedule Changes

Last Updated: June 22 2016
Article by Karen S. Lovitch and Kate F. Stewart

Last Friday afternoon CMS released its eagerly anticipated final rule (the Final Rule) implementing the Protecting Access to Medicare Act of 2014 (PAMA), which, together with the Final Rule, will make sweeping changes to the rate-setting process under the Medicare Clinical Laboratory Fee Schedule (MCLFS). According to CMS estimates, Medicare Part B payments for clinical diagnostic laboratory tests (CDLTs) will decrease by $390 million in fiscal year 2018 when the repricing will take effect. The Final Rule comes nearly nine months after CMS issued its proposed rule (the Proposed Rule) and long after PAMA's statutory deadline. Our previous coverage of the Proposed Rule is available here, here, and here.

In brief, PAMA requires CMS to update the MCLFS based on private payor rates for laboratory tests reported by "applicable laboratories." CMS will set MCLFS rates based on the weighted median of the reported private payor rates, with limits on the amount that the rate for a particular test can be decreased each year. As the first data collection period is already underway, affected laboratories should ensure that they have systems in place for gathering the requisite data and reporting to CMS in the first quarter of 2017. Virtually every laboratory will need a system for collecting the required data because many laboratories are unlikely to know in advance whether they must submit a report to CMS.

The most important differences between the Final Rule and the Proposed Rule include:

  • revised dates for data collection and submission and a shorter data collection period of six months;
  • a delayed effective date for new reimbursement rates of January 1, 2018;
  • a revised definition of "applicable laboratory" that is based on a lab's national provider identifier (NPI) rather than its taxpayer identification number (TIN), which should extend reporting obligations to many hospital outreach laboratories; and
  • expansion of the definition of advanced diagnostic laboratory test (ADLT) to include protein-only tests and elimination of the requirement that an ADLT must be performed only at a single laboratory facility.

New Dates

Due to CMS's lengthy delay in issuing the Final Rule – and strong pressure from Congress – CMS pushed out the effective date of the rate adjustments from January 1, 2017 to January 1, 2018. The Final Rule made corresponding changes to the initial data collection and reporting periods. The first data collection period will run from January 1, 2016 to June 30, 2016, with data submission occurring between January 1, 2017 to March 31, 2017.

Under the Proposed Rule, the initial data collection period was to run for six months, with subsequent collection periods to span a full year. The Final Rule instead makes each data collection period six months long, running from January 1 to June 30. Data submission will still occur between January 1 and March 31 in the year following the data collection. CMS believes that the additional six months between the end of data collection and the beginning of data submission will give laboratories sufficient time to collect and organize data. In some instances, laboratories will also need to use this six-month window to determine if they are exempt from reporting under the low expenditure threshold established by CMS, as further described below. Given that the initial 2016 data collection period is nearly over, laboratories must immediately begin working through this process.

Because data related to CDLTs will be reported to CMS every three years, the next reporting period will run from January through June 2019 with revisions to the CLFS made beginning January 1, 2021. Laboratories must report data related to ADLTs annually.

New Definition of "Applicable Laboratory"

The Final Rule made significant changes to the definition of "applicable laboratory" and the incorporated the concept of a "reporting entity." PAMA defines an "applicable laboratory" as a laboratory that receives a majority of its Medicare revenues under the MCLFS or the Medicare Physician Fee Schedule (MPFS). Multiple commenters, including the American Clinical Laboratory Association (ACLA) (comments) and the American Hospital Association (AHA) (comments), expressed concerned that CMS's proposal to define "applicable laboratory" based on an entity's TIN would exclude hospital outreach laboratories from reporting, which the organizations felt would skew pricing considering the volume of Medicare Part B testing performed by those laboratories. As noted by AHA, excluding hospital outreach laboratories would distort the payment data collected and lead to lower reimbursement rates.

Based on these concerns, CMS revised the definition of "applicable laboratory" in the Final Rule to mean an entity that bills Medicare Part B under its own NPI and receives more than 50% of its Medicare revenues during the applicable data collection period under the MCLFS or the MPFS. However, entities will still report at the TIN level. That is, each single corporate entity (with a single TIN) that operates a facility meeting the definition of an "applicable laboratory" must aggregate the reports of any applicable laboratories that it owns and make one consolidated report.

CMS also revised the low expenditure threshold for defining an "applicable laboratory." Under that threshold, a laboratory need not report if its MCLFS revenues received during the data collection period are less than $12,500, as opposed to the $50,000 threshold set by the Proposed Rule. As further described below, this threshold does not apply to reporting related to ADLTs.

Additional Guidance on Information to Report

The Final Rule provides much-needed additional guidance to laboratories on how to categorize private payor rates for reporting purposes. As laboratories prepare for reporting beginning on January 1, 2017, they should review the Final Rule's guidance carefully. The chart below summarizes a few key points regarding what should and should not be reflected in the data reported to CMS:



Tests performed and paid for during the data collection period

Claims subject to appeal

Non-contracted, out-of-network payments


Medicare Advantage payments

Tests paid for on a capitated basis

Medicaid managed care plan payments

Patient cost-sharing obligations (e.g., copayments, deductibles, coinsurance)

Price concessions (but not financial hardship waivers)

CMS will publish a list of HCPCS codes for which laboratories must report private payor rates. Reporting will not cover "not otherwise classified" or unlisted CPT codes.

Revised Definition for ADLTs

Based on feedback on the Proposed Rule's definition of an ADLT, which included only molecular pathology analyses of DNA or RNA, the Final Rule amended the definition to include tests involving the analysis of proteins. Additionally, CMS responded to comments that the Proposed Rule's definition of "single laboratory" for purposes of defining an ADLT was too limited because it did not reflect the corporate and operational structures of many laboratory companies. The definition of a "single laboratory" thus includes entities that own, or are owned by, the laboratory that furnishes the test.

The Final Rule also provides that the initial period for a new ADLT (i.e., the three quarters during which it is paid for by Medicare based on actual list charge amount) begins on the later of the date on which a Medicare Part B coverage determination for the test is made or the date on which CMS grants the test ADLT status.

What's Next?

In a press release issued not long after CMS released the Final Rule, ACLA sounded cautiously optimistic but made clear that its review is ongoing. We agree that the Final Rule seems to have made a bad situation a little better given that the Final Rule included significant concessions consistent with comments submitted by ACLA and other interested groups.

CMS has promised that additional sub-regulatory guidance will be forthcoming. Laboratories should track this additional guidance carefully as CMS is notorious for using this venue – which doesn't subject CMS to notice-and-comment requirements –to make under-the-radar policy decisions. With only a little more than nine months until the reporting deadline of March 31, 2017, laboratories have limited time to digest this entirely new data collection and reporting system, which will profoundly affect the laboratory industry for years to come.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Karen S. Lovitch
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions